John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol Medical AB, about Modufolin® in wake of the upcoming pivotal phase III study in metastatic colorectal cancer. The article discussed Modufolin as a potentially more effective product to combine with 5-fluorouracil (5-FU) rather than the conventional leucovorin in the treatment of colorectal cancer. Additional highlights were topics such as the history of folate based therapies, how the fact that some patients are unable, due to genetic prerequisites, to convert leucovorin into the active metabolite and how this has guided Isofol’s development of Modufolin®, containing the active metabolite of all folate-based therapeutics.
Furthermore, the article put the spotlight on how upcoming immune-oncology treatments will complement the regularly prescribed combination of 5-FU and leucovorin, and how the market of colorectal cancer will continue to grow, driven by the increased incidence of the cancer across the US and Europe.
Scrip intelligence – Pharmaceutical and biotech intelligence division of Informa
Scrip intelligence is a leading source of news and strategic analysis for the global pharmaceutical industry, providing customers with timely business-critical market and competitor intelligence. SCRIP has over 14,000 registered users consisting of mid-to-C-Level managers and executives working across all disciplines in pharmaceutical and biotech companies, worldwide. The service attracts 35,000 unique web visitors every month with potential partnering intentions.